Dynamic Changes in Circulating Tumour Cells Protein Expression
Dynamic Changes in RAS Gene Status and HER2 Expression in Circulating Tumour Cells: a Phase II Trial
Matteo's Friends
150 participants
Jan 14, 2019
INTERVENTIONAL
Conditions
Summary
This multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at University Magna Graecia) or managed by the treating clinician according to standard pathological criteria (standard management). The participants were assigned to trial groups with the use of block randomization stratified according to the enrolling center location metropolitan) and tumor stage (T3 or T4).
Eligibility
Inclusion Criteria2
- Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 to 2 (scores range from 0 to 5, with higher numbers reflecting greater disability) ,
- medically able to receive chemotherapy.
Exclusion Criteria3
- evidence of infective disease before enrollment ,
- a history of another primary cancer within the previous 3 years,
- the presence of synchronous primary colorectal cancer.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06314997